ConductScience.org, home
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
API referenceFor AI assistants

Trial · NCT03110770

Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

161 to 180 of 290

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousCholecystitisHepatobiliary disordersPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections030
seriousCholecystitisHepatobiliary disordersPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
seriousCholecystitisHepatobiliary disordersPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections030
seriousCholecystitisHepatobiliary disordersPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections01,162
seriousCholecystitisHepatobiliary disordersPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections11,161
seriousCholecystitis chronicHepatobiliary disordersPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections030
seriousCholecystitis chronicHepatobiliary disordersPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
seriousCholecystitis chronicHepatobiliary disordersPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections030
seriousCholecystitis chronicHepatobiliary disordersPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections01,162
seriousCholecystitis chronicHepatobiliary disordersPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections11,161
seriousCholelithiasisHepatobiliary disordersPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections030
seriousCholelithiasisHepatobiliary disordersPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
seriousCholelithiasisHepatobiliary disordersPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections030
seriousCholelithiasisHepatobiliary disordersPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections01,162
seriousCholelithiasisHepatobiliary disordersPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections11,161
seriousHepatitis acuteHepatobiliary disordersPart A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections030
seriousHepatitis acuteHepatobiliary disordersPart A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections030
seriousHepatitis acuteHepatobiliary disordersPart A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections030
seriousHepatitis acuteHepatobiliary disordersPart B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections01,162
seriousHepatitis acuteHepatobiliary disordersPart B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections11,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=9

API referenceFor AI assistants